United Therapeutics Corporation drugs

6 results

  • adcirca - tadalafil tablet

    (Tadalafil)
    United Therapeutics Corporation
    Adcirca is indicated for pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability, primarily studied in NYHA Functional Class II–III patients with idiopathic, heritable, or connective tissue disease-associated PAH.
    Medication Details
    Drug Interactions

  • orenitram - treprostinil tablet, extended release

    (Treprostinil)
    United Therapeutics Corporation
    Orenitram treats pulmonary arterial hypertension (PAH) in adults (WHO Group 1) to delay disease progression and improve exercise capacity. Most studied in WHO functional class II-III patients with idiopathic, heritable, or connective tissue disease-associated PAH.
    Medication Details
    Drug Interactions

  • remodulin - treprostinil injection, solution

    (Treprostinil)
    United Therapeutics Corporation
    Remodulin treats pulmonary arterial hypertension (PAH; WHO Group 1) in adults with NYHA Class II–IV symptoms to reduce exercise-related symptoms. Also indicated for patients transitioning from epoprostenol to slow clinical deterioration.
    Medication Details
    Drug Interactions

  • tyvaso - treprostinil inhalant

    (Treprostinil)
    United Therapeutics Corporation
    Tyvaso treats pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) in adults to improve exercise ability.
    Medication Details
    Drug Interactions

  • unituxin - dinutuximab injection

    (Dinutuximab)
    United Therapeutics Corporation
    Unituxin (dinutuximab) treats pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Used in combination with GM-CSF, IL-2, and 13-cis-retinoic acid.
    Medication Details
    Drug Interactions